Search results for "DAS"

showing 10 items of 4164 documents

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

2020

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI an…

Oncologymedicine.medical_specialtyTyrosine kinase inhibitorReview030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansNeoplastic transformation030212 general & internal medicineProtein Kinase InhibitorsTyrosine kinase inhibitorsCardiotoxicitybusiness.industryPonatinibChronic myeloid leukemiaImidazolesDisease ManagementMyeloid leukemiaImatinibPyridazinesDasatinibCardio-oncologyEarly DiagnosisNilotinibchemistryCardiovascular DiseasesPonatinibPonatinib . Tyrosine kinase inhibitors . Chronic myeloid leukemia . Cardio-oncology . ReviewCardiology and Cardiovascular MedicinebusinessBosutinibFollow-Up Studiesmedicine.drug
researchProduct

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

2010

Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious pulmonary complications [1]. The increased complexity of multimodality and high-dose treatment regimens with the intended benefit of augmented antineoplastic efficacy and prolonged disease-free survival, the use of a panel of novel drugs to treat malignant and nonmalignant hematologic conditions (e.g., azacytidine, bortezomib, cladribine, dasatinib, fludarabine, imatinib, lenalidomide, rituximab, and thalidomide), total body irradiation (TBI) and hematopietic stem cell transplantation (HSCT) have …

Oncologymedicine.medical_specialtybusiness.industryBortezomibTotal body irradiationFludarabineDasatinibTransplantationThalidomidehemic and lymphatic diseasesInternal medicinemedicineRituximabbusinessLenalidomidemedicine.drug
researchProduct

Outcome of patients with CML treated with dasatinib or nilotinib after failure of second prior TKIs.

2010

Abstract Abstract 2294 Background. The TKIs Nilotinib and Dasatinib offer additional therapeutic options for patients with CML who are resistant or intolerant to Imatinib. These agents, active against the majority of Imatinib resistant BCR-ABL mutated clones, have a different pattern of kinase target selectivity, pharmacokinetics parameters, cell uptake, efflux properties and adverse events profiles. Preliminary results suggest that some patients may respond to a second TKI used as third line therapy, but little is known about the long term benefit of such an approach.Aim of this collaborative Italian study was to verify the response (rate and duration) and the clinical outcome in patients …

Oncologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyComplete blood countAlpha interferonImatinibCell BiologyHematologyGene mutationBiochemistrySurgeryDasatinibNilotinibMedian follow-upInternal medicinemedicineAdverse effectbusinessmedicine.drug
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Ādas melanomas radikālās ķirurģijas ārstēšanas rezultāti Rīgas austrumu klīniskās universitātes slimnīcas stacionārā "Latvijas Onkoloģijas centrs"

2017

Tēmas aktualitāte: Ādas melanomas sastopamība turpina ik gadu pieaugt, ne tikai visā pasaulē, bet arī Latvijā. Neskatoties uz plaši veiktajiem sabiedrības izglītošanas pasākumiem, melanomas pacientu mirstība nav ievērojami samazinājusies. Mērķis: Raksturot saslimstību ar ļaundabīgo ādas melanomu un izvērtēt sargmezglu biopsijas rezultātus. Materiāli: Aprakstošs retrospektīvs pētījums tika veikts Rīgas Austrumu klīniskās universitātes slimnīcas stacionārā “Latvijas Onkoloģijas centrs”. Pētījumā tika iekļauti 134 pacienti ar pirmreizēji diagnosticētu ādas ļaundabīgo melanomu, un radikāli ķirurģiski ekscidēta laika periodā no 2012.gada janvāra līdz 2012.gada decembrim. Dati tika ievākti no pac…

OnkoloģijaDermatoloģijaBreslovsSargmezgla biopsijaĀdas melanomaMedicīna
researchProduct

Bazaliomu plakanšūnu karcinomas TNM stadiju un histoloģisko formu salīdzinājums pacientiem Latvijas Onkoloģijas Centrā

2018

Tēmas aktualitāte. Ļaundabīgo ādas audzēju sastopamība ik gadu turpina pieaugt gan Latvijā, gan visā pasaulē. Par spīti plaši veiktajiem sabiedrības izglītošanas pasākumiem un programmām, ādas audzēju pirmreizējo gadījumu skaits nav mazinājies. Mērķis. Raksturot saslimstību ar ādas bazālo šūnu karcinomu un plakanšūnu karcinomu, un izvērtēt to augšanas veidu saistību ar slimības TNM stadiju. Materiāli. Retrospektīvs pētījums tika veikts Rīgas Austrumu klīniskās universitātes slimnīcas stacionārā “Latvijas Onkoloģijas centrs”. Pētījumā iekļauti 211 pacienti ar diagnosticētiem un redikāli ķirurģiski ekscidētiem bazaliomas un plakanšūnu karcinomas ādas veidojumiem laika periodā no 2016.gada jan…

OnkoloģijaĀdas audzējiPlakanšūnu karcinomaBazaliomaMedicīna
researchProduct

Insulin withdrawal in diabetic kidney disease : What are we waiting for?

2021

The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease (CKD), and these patients often present high morbidity and mortality rates, particularly in those patients with poorly controlled risk factors. Furthermore, many are overweight or obese, due primarily to insulin compensation resulting from insulin resistance. In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular targets; however…

Opinionmedicine.medical_specialtyinsulinHealth Toxicology and Mutagenesismedicine.medical_treatmentRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologyOverweight03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseInternal medicinemedicineHumansHypoglycemic AgentsInsulinDiabetic NephropathiesSGLT2iDiabetic kidney diseaseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetisbusiness.industryInsulinMortality ratePublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseRepaglinideCardiovascular diseaseGLP-1RAdiabetic kidney diseaseCor MalaltiesDiabetes Mellitus Type 2Medicinemedicine.symptombusinessKidney diseasemedicine.drug
researchProduct

Nosotros, también con Garzón

2009

OposiciónDemocraciaConvención de GinebraVidal-Beneyto JoséManos limpiasGarzónJusticia democráticaVerdugosFranquismoCrímenes del franquismoDerechos HumanosReparaciónPasadoESPAÑAJusticiaEspectáculoMEMORIA DEMOCRÁTICAInvestigaciónNaciones UnidasJudicaturaJuecesMemoria históricaPublicaciones: Obra periodística: Cartas al director
researchProduct

Experimental demonstration of fractional order differentiation using a long-period grating-based in-fiber modal interferometer

2016

In this work we demonstrate both, experimentally and theoretically, that a long-period grating-based in-fiber modal interferometer can perform an all-optical arbitrary-order fractional differentiation. Experimentally, we fractionally differentiated to the 0.5th order a secant hyperbolic-like pulse of 23 ps time width provided by a 1039.5 nm emission wavelength modelocked fiber laser, with a chirp parameter of −30. An analytical expression relating the fractional order of differentiation n with the characteristics of the modal interferometer was also derived, with the purpose to simplify the design procedure. The proposal was corroborated also numerically. This device may find applications i…

Optical fiberCiencias FísicasPhase (waves)Physics::Optics02 engineering and technologyGratingMach–Zehnder interferometer01 natural sciencesFRACTIONAL DIFFERENTIATIONlaw.invention010309 optics020210 optoelectronics & photonicsOpticslawFiber laser0103 physical sciences0202 electrical engineering electronic engineering information engineeringChirpElectrical and Electronic EngineeringPhysical and Theoretical ChemistryFIBER OPTICSPhysicsbusiness.industryAtomic and Molecular Physics and OpticsElectronic Optical and Magnetic MaterialsPulse (physics)AstronomíaWavelengthLONG-PERIOD GRATINGbusinessMACH&ndash;ZEHNDERCIENCIAS NATURALES Y EXACTASOptics Communications
researchProduct

Smart structures through nontraditional design of Tuned Mass Damper Inerter for higher control of base isolated systems

2020

Abstract This paper introduces a smart structure design through the definition of an innovative passive control strategy, referred to as New Tuned Mass Damper Inerter (New TMDI), coupled with a base isolation system (BI), to control displacements in base isolated structures under seismic excitations. The herein proposed New TMDI comprises a recently developed nontraditional Tuned Mass Damper (known as New TMD), in which a secondary mass system is connected to the base plate of the BI system by a spring and to the ground by a dashpot, and of an inerter device placed in parallel with the damper. An optimization procedure which minimizes the base displacement variance of the BI system, conside…

Optimal designOptimal designComputer science02 engineering and technology01 natural sciencesDashpot010305 fluids & plasmaslaw.inventionDamperNontraditional layout0203 mechanical engineeringlawTuned mass damper0103 physical sciencesInerterGeneral Materials ScienceCivil and Structural EngineeringTuned Mass Damperbusiness.industryMechanical EngineeringBase-isolation systemWhite noiseStructural engineeringCondensed Matter PhysicsBase (topology)020303 mechanical engineering & transportsInerterMechanics of MaterialsBase isolationSettore ICAR/08 - Scienza Delle CostruzionibusinessMechanics Research Communications
researchProduct